Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Hits Walls In Fending Off Prograf Generics; Options Limited

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - Astellas' last ditch efforts to prevent the launch of Sandoz' generic Prograf (tacrolimus) failed last week, and as the company "evaluates its next course of action" for its top-selling product, its options do not look promising

You may also be interested in...



Japan Grants Astellas' Prograf Approval For Additional Indication Myasthenia Gravis

TOKYO - Astellas' immunosuppressant for organ transplant Prograf (tacrolimus) was granted an additional indication approval by Japan's Ministry for Health, Labor and Welfare for myasthenia gravis, an autoimmune disorder characterized by muscle weakness and fatigue, the company reported Oct. 16

Japan Grants Astellas' Prograf Approval For Additional Indication Myasthenia Gravis

TOKYO - Astellas' immunosuppressant for organ transplant Prograf (tacrolimus) was granted an additional indication approval by Japan's Ministry for Health, Labor and Welfare for myasthenia gravis, an autoimmune disorder characterized by muscle weakness and fatigue, the company reported Oct. 16

Facing Patent Losses, Astellas Funds Genome Laboratory And Reorganizes Drug Discovery Functions

Astellas announced Sept. 1 it established the Genome Medical Science Laboratory at the University of Tokyo. The laboratory is looking to elucidate the mechanism of tumorigenesis through a large analysis of clinical samples using genomics technologies to develop new cancer treatments

Related Content

UsernamePublicRestriction

Register

SC072535

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel